Navigation Links
Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
Date:3/5/2008

in these studies, research has demonstrated that there is a 2-5 fold increased risk of cardiovascular disease in people with both diabetes and the Hp 2-2 genotype (approximately 40 percent of all diabetes patients).

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company believes it has identified several product candidates that represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events de
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
2. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
3. Synvista Therapeutics to be Featured on Wallst.net
4. Synvista Therapeutics to Present at the BIO InvestorForum 2007
5. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
6. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
7. CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
8. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
10. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
11. CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by filmmakers, the ... dynamic collection of legal medical cannabis stories ever assembled. , Cannavoices profiles ...
(Date:6/29/2015)... 2015 BioNano Genomics, Inc., the leader in ... announced today that a collaboration led by the Icahn ... creation of the first comprehensive analysis of a diploid ... for sequencing and genome mapping. This study, published today ... of the contiguous diploid human genome assembly obtained without ...
(Date:6/29/2015)... ... , ... The StampedeCon 2015 Big Data Conference will be taking ... row, will bring top technology professionals to St. Louis. Top industry speakers will share ... technology. The event is proudly sponsored by DataStax, Cisco, World Wide Technology, Hortonworks, OCI, ...
(Date:6/26/2015)... , June 26, 2015   ... ), a pet therapeutics company focused on ... biopharmaceutical products for companion animals, today announced ... study of capromorelin (AT-002), the company,s innovative ... is a small molecule that mimics ghrelin, ...
Breaking Biology Technology:Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5
... ... Service, the global leader in chemical information and a division of the American ... pathways and improve productivity for researchers working in the chemical, pharmaceutical, biotechnology, and ... in every aspect of the chemical R&D process. , ...
... ... insight into FDA Final Guidance , ... Pittsburgh (Vocus) March 24, 2010 -- invivodata inc. , the ... along with its scientific and regulatory consulting division, PRO Consulting , today announced a ...
... from a pollutant into useful products that could help both ... used to: convert carbon dioxide (CO 2 ... for laptops and mobile phones at University College London, produce ... concept at Imperial College London, remove CO 2 from ...
Cached Biology Technology:New SciFinder Features Reveal More Synthetic Pathways and Improve Productivity 2New SciFinder Features Reveal More Synthetic Pathways and Improve Productivity 3invivodata Offers Complimentary PRO Gap Analysis 2invivodata Offers Complimentary PRO Gap Analysis 3From pollutant to profit -- nanoscience turns carbon on its head 2From pollutant to profit -- nanoscience turns carbon on its head 3
(Date:6/17/2015)... 17, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced that Xiaomi, one of the world,s largest ... ClearPad ® family of capacitive touchscreen solutions ... (DDICs) for its latest smartphones, the Xiaomi Mi ... full in-cell display solutions and DDICs in discrete ...
(Date:6/16/2015)... 2015  With the increasing number and severity of ... concern. The recent compromise of Federal employee data ... authentication within government agencies. HYPR Corp. announced ... (OTP) authenticator, has been submitted for testing and approval ... validation for tamper proofing. The proliferation ...
(Date:6/15/2015)... , June 16, 2015 ... Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies ... Forecast to 2020" published by MarketsandMarkets, The Natural Language ... at a CAGR of 18.4% for the forecast period ... and   46 F igures spread   through ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... who are taking part in a nationwide initiative, Project ... unusually early, perhaps as a result of climate change. ... and foliage, amassing thousands of observations from across the ... changing climate. The project, started as a pilot ...
... available in Spanish . , In all cancers, ... cells show high Myc protein levels. Excess Myc causes cells to ... tumours. One of the most pressing questions about Myc is how ... a study using the Drosophila , researchers at the Institute ...
... tinnitus is low, according to new research from the Norwegian ... study to measure the heritability of tinnitus. ,The ... it is hereditary. Prevalence of tinnitus was 15.1 percent, which ... is a symptom with a variety of underlying causes, such ...
Cached Biology News:'10 most wanted' plants inspected for clues to climate change 2'10 most wanted' plants inspected for clues to climate change 3New data on the regulation of a protein that is altered in all cancers 2
Synaptic Vesicle I Sampler Kit 10g each...
Mouse monoclonal [3A7.A11] to Thymidylate Synthase ( Abpromise for all tested applications). entrezGeneID: 7298 SwissProtID: P04818...
Mouse monoclonal [N7519] to NR0B2 ( Abpromise for all tested applications). Antigen: E.coli expressed recombinant full length protein (Human) NR0B2 Entrez Gene ID: 8431 Swiss Protein ID: ...
Integrins Sampler Kit 10g each...
Biology Products: